LH
Laboratory Corp of America Holdings
Laboratory Corp of America Holdings historical holders
total: 10
Lountzis Asset Management Laboratory Corp of America Holdings transactions over time
- Total transactions:
- 14
- New positions:
- 1
- Added:
- 1
- Reduced:
- 12
- Held since:
- 2020 Q2
- Held for:
- 24 quarters
- Latest activity:
- 2026 Q1
Paul Lountzis has been an institutional investor in Laboratory Corp of America Holdings (LH) since 2020 Q2. According to 2026 Q1 report, Paul Lountzis holds 8,999 shares with a market value of roughly $2.40M representing 0.88% of their equity portfolio. The fund/company first acquired LH in 2020 Q2, initially purchasing 10,322 shares. Since the initial investment, Lountzis Asset Management has made 13 more transactions in this position.
Does Paul Lountzis still hold LH?
Yes, Paul Lountzis continues to hold Laboratory Corp of America Holdings (LH). According to their 2026 Q1 report, they maintain a position of 8,999 shares valued at approximately $2.40M, representing 0.88% of their equity portfolio.
When did Paul Lountzis first invest in LH?
Paul Lountzis first invested in Laboratory Corp of America Holdings (LH) in 2020 Q2 at the reported quarter-end price of $166.15 per share, acquiring 10,322 shares in their initial purchase.
What is Paul Lountzis's average cost basis for LH?
Based on historical transaction data, Paul Lountzis's estimated cost basis for Laboratory Corp of America Holdings (LH) is approximately $166.67 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $166.67
- Weighted AVG sell price:
- $228.15
LH transactions history by Lountzis Asset Management
14 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
0.88%
|
8,999
|
$266.81
|
$2,401,023
|
-0.70% (-63)
|
-0.01%
|
|
2025 Q4
|
0.81%
|
9,062
|
$250.88
|
$2,273,475
|
-1.27% (-117)
|
-0.01%
|
|
2025 Q1
|
0.80%
|
9,179
|
$229.60
|
$2,107,498
|
-1.39% (-129)
|
-0.01%
|
|
2024 Q4
|
0.90%
|
9,308
|
$229.32
|
$2,134,511
|
-2.32% (-221)
|
-0.02%
|
|
2024 Q3
|
0.89%
|
9,529
|
$223.48
|
$2,129,540
|
+1.01% (+95)
|
+0.01%
|
|
2024 Q2
|
0.90%
|
9,434
|
$203.51
|
$1,919,913
|
-0.88% (-84)
|
-0.01%
|
|
2023 Q4
|
1.18%
|
9,518
|
$227.29
|
$2,163,346
|
-0.19% (-18)
|
-0%
|
|
2023 Q2
|
1.15%
|
9,536
|
$218.75
|
$2,086,000
|
-2.65% (-260)
|
-0.03%
|
|
2022 Q4
|
1.44%
|
9,796
|
$244.49
|
$2,395,000
|
-2.34% (-235)
|
-0.04%
|
|
2022 Q3
|
1.39%
|
10,031
|
$204.77
|
$2,054,000
|
-2.51% (-258)
|
-0.04%
|
|
2022 Q2
|
1.61%
|
$234.33
|
-0.05% (-5)
|
|||
|
2021 Q4
|
1.85%
|
$314.21
|
-0.17% (-18)
|
|||
|
2020 Q3
|
1.67%
|
$188.23
|
-0.10% (-10)
|
|||
|
2020 Q2
|
1.63%
|
$166.15
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.